Publications by authors named "Takatomo Yoneoka"

Introduction/aims: Edaravone in amyotrophic lateral sclerosis (ALS) was analyzed in two phase 3 studies (MCI186-16 and MCI186-19). Those trials enrolled patients with Japanese ALS severity grades 1 and 2 (less severe ALS), but many patients progressed to grades 3 and 4 during the double-blind treatment period. The placebo patients who initiated edaravone treatment in the open-label periods provided an opportunity to assess the effects of edaravone in more severe ALS.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how baseline urate levels affect functional changes in ALS patients receiving edaravone treatment, using data from multiple clinical trials.
  • Results show that patients treated continuously with edaravone experienced a slower decline in both ALSFRS-R scores and urate levels compared to those who received placebo, regardless of their initial urate levels.
  • The findings suggest that monitoring urate levels may help predict disease progression in ALS patients undergoing edaravone treatment, particularly for those with higher baseline urate levels.
View Article and Find Full Text PDF

Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) patients. We conducted a 36-week confirmatory study, consisting of 12-week pre-observation period followed by 24-week treatment period. Patients received placebo or edaravone i.

View Article and Find Full Text PDF